Saralasin
Saralasin is a synthetic octapeptide angiotensin II receptor antagonist, one of the earliest competitive blockers of the renin-angiotensin system, used historically for the diagnosis of renovascular hypertension and angiotensin-dependent hypertension. As a partial agonist at angiotensin II receptors, it competitively displaces endogenous angiotensin II, transiently lowering blood pressure in renin-dependent hypertension. It has been largely replaced by orally active ARBs and ACE inhibitors in clinical practice.
Peso Molecular
912,0000 g/mol
LogP
-2,60
TPSA
358,00 Ų
Regra dos 5 de Lipinski
Reprovado
Mecanismo de Ação
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C
InChI
InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1
Molecular Formula
C42H65N13O10
HBD / HBA
12 / 13
Ligações Rotacionáveis
25
Átomos Pesados
65
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Saralasin is a synthetic octapeptide angiotensin II receptor antagonist, one of the earliest competitive blockers of the renin-angiotensin system, used historically for the diagnosis of renovascular hypertension and angiotensin-dependent hypertension. As a partial agonist at angiotensin II receptors, it competitively displaces endogenous angiotensin II, transiently lowering blood pressure in renin-dependent hypertension. It has been largely replaced by orally active ARBs and ACE inhibitors in clinical practice.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Saralasin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL938. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6324663. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="saralasin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/saralasin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/saralasin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/saralasin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="saralasin"></drugfyi-drug>